|
GB0703406D0
|
|
T Cell therapies
|
|
GB0702799D0
|
|
Tcells presenting modified CD8
|
|
GB0701617D0
|
|
Bifunctional proteinaceous complexes
|
|
GB0701618D0
|
|
T cell receptor-based hypersensitivity therapeutics
|
|
GB0700312D0
|
|
T cell receptor-based hypersensitivity therapies
|
|
GB0623539D0
|
|
Polypeptides
|
|
GB0619251D0
|
|
T cell therapies
|
|
WO2006125962A2
|
|
T cell receptors which specifically bind to vygfvracl-hla-a24
|
|
GB0606238D0
|
|
Kinase inhibition
|
|
GB0603522D0
|
|
Kinase inhibition
|
|
GB0602693D0
|
|
T cells presenting modified CD8
|
|
GB0601738D0
|
|
T cell receptor-based hypersensitivity therapeutics
|
|
GB0601742D0
|
|
Bifunctional proteinaceous complexes
|
|
GB0600282D0
|
|
T cell receptor-based hypersensitivity therapeutics
|
|
GB0524477D0
|
|
Isolated T cell receptors which specifically bind to vygfvracl-hla-24
|
|
EP1812574A2
|
|
Soluble bifunctional proteins
|
|
MX2007003910A
|
|
T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.
|
|
GB0516487D0
|
|
High affinity HIV T cell receptors
|
|
WO2006000830A2
|
|
Cells expressing a modified t cell receptor
|
|
GB0512480D0
|
|
Cells transformed with nucleic acid
|
